Core Viewpoint - Biogen Inc. has demonstrated strong stock performance and operational results, driven by its newer product portfolio, despite a projected revenue decline for fiscal year 2026 [2][4][5]. Company Overview - Biogen Inc. is headquartered in Cambridge, Massachusetts, focusing on therapies for severe neurological, immunological, and rare disorders, with a market cap of approximately $28.8 billion [1]. Stock Performance - Over the past 52 weeks, Biogen's shares have appreciated 41.9%, significantly outperforming the S&P 500 Index, which gained 11.8% [2]. - Year-to-date, BIIB stock is up 11.7%, while the broader index has seen a marginal decline [2]. - The iShares Biotechnology ETF has risen 25.9% over the last 52 weeks, indicating that Biogen's gains are notably higher than sector averages [3]. Financial Results - In Q4 fiscal 2025, Biogen reported a revenue decline of 7.1% year over year to $2.28 billion, surpassing analyst estimates of $2.2 billion [3]. - Adjusted EPS for the quarter reached $1.99, exceeding expectations of $1.63 [3]. Product Portfolio - The performance in Q4 was attributed to strong momentum in newer products, including Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively generated over $1 billion in annual revenue [4]. Future Projections - For fiscal year 2026, total revenue is projected to decline by a mid-single-digit percentage compared to 2025, but non-GAAP diluted EPS is expected to be in the range of $15.25 to $16.25 [5]. - Analysts project diluted EPS to grow 3.3% year over year to $15.79 for fiscal year 2026 [6]. Analyst Ratings - Wall Street currently rates BIIB as "Moderate Buy," with 14 out of 34 analysts recommending "Strong Buy," one suggesting "Moderate Buy," and 19 advising "Hold" [6].